U.S. High Court Endorses Federal Circuit Enablement Standard

Mealey's (May 18, 2023, 1:22 PM EDT) -- WASHINGTON, D.C. — A unanimous U.S. Supreme Court on May 18 affirmed trial court and circuit court rulings that two Amgen Inc. patents on anti-cholesterol antibodies are not sufficiently enabled because they seek to cover “potentially millions” of antigens that they do not claim....